Advanced glycation end-products downregulating intervertebral disc cell production of proteoglycans in vitro.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 17048769.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors sought to clarify the role, if any, of advanced glycation end-products (AGEs) in disc degeneration. Intervertebral discs were analyzed for the presence of AGEs and of their receptor (RAGE) by immunohistochemical analysis. Reverse transcriptase polymerase chain reaction (RT-PCR) was performed to detect any RAGE gene expression, and real-time PCR was used to quantify messenger RNA (mRNA) levels of aggrecan and collagen types I and II in nucleus pulposus cells treated with AGEs. Aggrecan protein concentration was determined by enzyme-linked immunosorbent assay. Immunohistochemical analysis revealed that AGEs and RAGE were localized in the nucleus pulposus of the intervertebral disc. Advanced glycation end-products were found to significantly suppress the expression of aggrecan at both mRNA and protein levels in a dose- and time-dependent manner. The levels of collagen types I and II remained unchanged after treatments with AGEs. These results suggest that the accumulation of AGEs and their interaction with their receptor in the nucleus pulposus might result in the downregulation of aggrecan production responsible for disc degeneration.
Medical subject headings
- Chondroitin Sulfate Proteoglycans
- Extracellular Matrix Proteins
- Fibrillar Collagens
- Glycation End Products, Advanced
- Intervertebral Disc
- Lectins, C-Type
- Lumbar Vertebrae
- Proteoglycans
Anatomy
- lumbar spine